Cwm LLC Has $248,000 Stake in LivaNova PLC $LIVN

Cwm LLC boosted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 533.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,517 shares of the company’s stock after buying an additional 4,646 shares during the quarter. Cwm LLC’s holdings in LivaNova were worth $248,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC increased its position in LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after buying an additional 407 shares during the last quarter. Parallel Advisors LLC grew its position in shares of LivaNova by 1,312.3% in the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after purchasing an additional 958 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of LivaNova by 415.4% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock valued at $58,000 after purchasing an additional 1,184 shares during the last quarter. Strs Ohio acquired a new stake in shares of LivaNova in the first quarter valued at about $130,000. Finally, Central Pacific Bank Trust Division grew its position in shares of LivaNova by 9.5% in the second quarter. Central Pacific Bank Trust Division now owns 4,827 shares of the company’s stock valued at $217,000 after purchasing an additional 420 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

Shares of LivaNova stock opened at $54.28 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The firm has a market cap of $2.96 billion, a P/E ratio of -13.95 and a beta of 0.95. The firm has a 50 day simple moving average of $54.55 and a 200 day simple moving average of $47.25. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $58.91.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. LivaNova’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.93 earnings per share. Sell-side analysts predict that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research report on Wednesday, September 3rd. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. The Goldman Sachs Group set a $55.00 price target on LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Finally, Barclays raised their price target on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.